(VIANEWS) – IBA (IBAB.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| IBA (IBAB.BR) | €14.60 | 1.43% | 5.01% |
| VETOQUINOL (VETO.PA) | €90.40 | 0.91% | 10.37% |
| SARTORIUS STED BIO (DIM.PA) | €260.90 | 0.61% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. IBA (IBAB.BR)
1.43% Forward Dividend Yield and 5.01% Return On Equity
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €0.2.
PE Ratio
IBA has a trailing twelve months price to earnings ratio of 73. Meaning, the purchaser of the share is investing €73 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.01%.
Volatility
IBA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.96%, a negative 0.54%, and a positive 1.20%.
IBA’s highest amplitude of average volatility was 0.96% (last week), 1.11% (last month), and 1.20% (last quarter).
Volume
Today’s last reported volume for IBA is 3877 which is 66.57% below its average volume of 11599.
More news about IBA.
2. VETOQUINOL (VETO.PA)
0.91% Forward Dividend Yield and 10.37% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.06.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 22.27. Meaning, the purchaser of the share is investing €22.27 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.37%.
More news about VETOQUINOL.
3. SARTORIUS STED BIO (DIM.PA)
0.61% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €8.03.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 32.49. Meaning, the purchaser of the share is investing €32.49 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Sales Growth
SARTORIUS STED BIO’s sales growth is negative 18.5% for the ongoing quarter and negative 22.4% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SARTORIUS STED BIO’s EBITDA is 124.05.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be oversold (<=20).
More news about SARTORIUS STED BIO.
